Sorrento Therapeutics Inc

+0.03 (+2.44%)
7:59:27 PM EDT: $1.29 +0.03 (+2.38%)
Products, Regulatory

Sorrento Therapeutics Completes Enrollment Of Phase 2 Clinical Trial Of Resiniferatoxin (RTX) For Treatment Of Knee Pain In Moderate To Severe Osteoarthritis Of The Knee (OAK) Patients

Published: 09/26/2022 13:57 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (rtx) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (oak) Patients.
Sorrento Therapeutics - Plans to Conduct an End of Phase 2 Meeting With FDA for Rtx Program As Soon As Initial Top Line Data is Available.
Sorrento Therapeutics Inc - Initial Efficacy Data on Pain Relief Parameters Expected to Be Available in Q2 2023.